Central Bank & Trust Co. Has $1.16 Million Holdings in Boston Scientific Corporation $BSX

Key Points

• Central Bank & Trust Co. increased its holdings in Boston Scientific by 30.5%, owning 10,759 shares worth approximately $1.16 million at the end of the last quarter.
• Insiders sold a total of 174,214 shares of company stock valued at about $18.4 million over the last quarter, indicating significant trading activity among executives.
• Boston Scientific reported a 22.8% revenue increase year-over-year, reaching $5.06 billion in Q2, surpassing analysts' expectations of $4.89 billion.

Central Bank & Trust Co. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 30.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,759 shares of the medical equipment provider's stock after purchasing an additional 2,517 shares during the quarter. Central Bank & Trust Co.'s holdings in Boston Scientific were worth $1,156,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. NS Partners Ltd raised its stake in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after buying an additional 5,704 shares in the last quarter. Neville Rodie & Shaw Inc. raised its stake in shares of Boston Scientific by 95.9% in the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider's stock valued at $4,883,000 after buying an additional 22,255 shares in the last quarter. Reliant Investment Partners LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at $237,000. Ascent Group LLC raised its stake in shares of Boston Scientific by 226.5% in the 1st quarter. Ascent Group LLC now owns 49,942 shares of the medical equipment provider's stock valued at $5,038,000 after buying an additional 34,645 shares in the last quarter. Finally, Swedbank AB raised its stake in shares of Boston Scientific by 2.8% in the 1st quarter. Swedbank AB now owns 1,314,230 shares of the medical equipment provider's stock valued at $132,580,000 after buying an additional 35,300 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BSX shares. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Leerink Partners assumed coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price on the stock. Truist Financial upped their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, Robert W. Baird increased their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and an average target price of $118.04.

Insider Buying and Selling at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 over the last quarter. Insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

Shares of BSX opened at $99.75 on Tuesday. The stock has a market capitalization of $147.80 billion, a P/E ratio of 59.38, a P/E/G ratio of 2.47 and a beta of 0.65. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a 50 day moving average of $104.78 and a 200-day moving average of $102.24. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same period last year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.